身体轮后食欲下降与低水平的依赖葡萄糖的胰岛素型多相关
Mohamed Badie Ahmed1, Asma Syed2, Suhail A Doi2
1Department of Population Medicine, College of Medicine, QU Health, Qatar University, Doha, Qatar; Plastic Surgery Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Journal of plastic, reconstructive & aesthetic surgery : JPRAS
|November 13, 2025
概括
较低的依赖葡萄糖的胰岛素型多 (GIP) 水平与身体轮手术后食欲下降相关. 这表明GIP可能是调节养行为的关键激素,并可能为未来的肥胖治疗提供信息.
科学领域:
- 内分泌学 在内分泌学.
- 代谢手术 代谢手术
- 调节食欲 调节食欲是什么意思
背景情况:
- 肠道激素调节对于腹控制在腹术后至关重要.
- 肠道激素在身体轮程序后对食欲调节的作用尚不清楚.
研究的目的:
- 为了研究肠道激素水平与接受身体轮手术的患者的食欲抑制之间的关联.
- 为了确定潜在的荷尔蒙标志物来减少这一群体的食欲.
主要方法:
- 对47名接受腹部整形,大腿升降或下体升降的成年人进行前性研究.
- 在手术前和手术后评估食欲,使用营养委员会食欲调查问卷.
- 测量了依赖葡萄糖的胰岛素型多 (GIP) 和活性格林的血水平.
主要成果:
- 手术后较低的GIP水平 (51.4 pg/ml) 与基线 (112.2 pg/ml) (p=0.035) 相比,与相对较低的食欲 (RLA) 有显著的关联.
- 活性格林和之前的减肥手术显示了与RLA相关的趋势,但没有统计学意义.
- 对RLA的预测模型具有中度的区分能力 (AUC=0.695).
结论:
- 葡萄糖依赖型胰岛素型多 (GIP) 是身体轮手术后抑制食欲的潜在激素标志物.
- 这些发现支持GIP在养行为肠-大脑调节中的作用.
- 结果可能会为未来的肥胖管理药理学策略提供信息,针对GIP途径.
相关概念视频
Regulation of Food Intake
2.3K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
2.3K
Glucagon-like Receptor Agonists
828
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
828
Hypoglycemia and Glucagon
787
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
787
Dipeptidyl Peptidase 4 Inhibitors
570
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
570
Hormones Regulating Blood Glucose
6.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.4K
Insulin: Dosing Regimen and Adverse Effects
665
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
665


